Members of the IQVIA Biotech clinical development team will be at the Outsourcing in Clinical Trials New England meeting and would be delighted to discuss your drug development program.

Visit us at IQVIA Biotech booth #73

Predictive Clinical Development: De-Risking and Accelerating Clinical Development

October 27 at 2:45 PM

Presented by Peter Ronco, President, IQVIA Biotech

For biotech and emerging biopharma companies, every development decision carries significant implications for timelines, funding milestones, and investor confidence. As pressure mounts to advance programs faster, the most successful organizations are using predictive analytics, integrated development planning, and data-driven decision-making to de-risk clinical development and accelerate execution across the entire development lifecycle.

Join this session to learn how biotech sponsors can reduce uncertainty from first-in-human studies through pivotal trials by reducing delays between phases, increasing cross-functional coordination, and improving operational execution to bring therapies to patients faster.

Key Discussion Points:

• Accelerating transitions between Phase I, II, and III studies.
• Reducing operational "white space" between development milestones.
• Increasing parallelization of clinical, regulatory, and operational workstreams.
• Improving enrollment forecasting and predictability.
• Driving efficiency and speed across the end-to-end development lifecycle.

Biotech Power Shift: Navigating China’s Rise in Global Clinical Development

October 28 at 1:30 PM

Panelists to include Peter Ronco, President, IQVIA Biotech

China’s life sciences sector is rapidly reshaping the global biotech landscape, with a growing pipeline of high-quality assets attracting significant international investment and licensing activity. This session will explore how this shift is impacting clinical development strategies, regulatory frameworks, and competitive dynamics. From navigating cross-border partnerships to understanding evolving FDA perspectives, join industry leaders as they unpack what this means for outsourcing, trial design, and the future of global collaboration.

• The surge of high-quality assets from China: what’s driving the acceleration?
• Licensing trends: why Western pharma is increasingly looking East.
• Regulatory implications: how the FDA and global bodies are adapting.
• Geopolitics vs innovation: balancing risk, access, and opportunity in trial strategy.